000177465 001__ 177465
000177465 005__ 20240229133741.0
000177465 0247_ $$2doi$$a10.1016/j.ygyno.2021.10.088
000177465 0247_ $$2pmid$$apmid:34776242
000177465 0247_ $$2ISSN$$a0090-8258
000177465 0247_ $$2ISSN$$a1095-6859
000177465 0247_ $$2altmetric$$aaltmetric:117122264
000177465 037__ $$aDKFZ-2021-02557
000177465 041__ $$aEnglish
000177465 082__ $$a610
000177465 1001_ $$aKhoja, Lilah$$b0
000177465 245__ $$aEndometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
000177465 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2022
000177465 3367_ $$2DRIVER$$aarticle
000177465 3367_ $$2DataCite$$aOutput Types/Journal article
000177465 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642512416_14352
000177465 3367_ $$2BibTeX$$aARTICLE
000177465 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177465 3367_ $$00$$2EndNote$$aJournal Article
000177465 500__ $$a2022 Jan;164(1):195-201
000177465 520__ $$aTo evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs).Overall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99).The hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation.
000177465 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177465 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177465 650_7 $$2Other$$aEndometriosis
000177465 650_7 $$2Other$$aHormone therapy
000177465 650_7 $$2Other$$aHysterectomy
000177465 650_7 $$2Other$$aOvarian cancer
000177465 7001_ $$aWeber, Rachel Palmieri$$b1
000177465 7001_ $$aGroup, Australian Ovarian Cancer Study$$b2$$eCollaboration Author
000177465 7001_ $$aWebb, Penelope M$$b3
000177465 7001_ $$aJordan, Susan J$$b4
000177465 7001_ $$aMuthukumar, Aruna$$b5
000177465 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b6$$udkfz
000177465 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée T$$b7$$udkfz
000177465 7001_ $$aJensen, Allan$$b8
000177465 7001_ $$aKjaer, Susanne K$$b9
000177465 7001_ $$aRisch, Harvey$$b10
000177465 7001_ $$aDoherty, Jennifer Anne$$b11
000177465 7001_ $$aHarris, Holly R$$b12
000177465 7001_ $$aGoodman, Marc T$$b13
000177465 7001_ $$aModugno, Francesmary$$b14
000177465 7001_ $$aMoysich, Kirsten$$b15
000177465 7001_ $$aBerchuck, Andrew$$b16
000177465 7001_ $$aSchildkraut, Joellen M$$b17
000177465 7001_ $$aCramer, Daniel$$b18
000177465 7001_ $$aTerry, Kathryn L$$b19
000177465 7001_ $$aAnton-Culver, Hoda$$b20
000177465 7001_ $$aZiogas, Argyrios$$b21
000177465 7001_ $$aPhung, Minh Tung$$b22
000177465 7001_ $$aHanley, Gillian E$$b23
000177465 7001_ $$aWu, Anna H$$b24
000177465 7001_ $$aMukherjee, Bhramar$$b25
000177465 7001_ $$aMcLean, Karen$$b26
000177465 7001_ $$aCho, Kathleen$$b27
000177465 7001_ $$aPike, Malcolm C$$b28
000177465 7001_ $$aPearce, Celeste Leigh$$b29
000177465 7001_ $$aLee, Alice W$$b30
000177465 773__ $$0PERI:(DE-600)1467974-7$$a10.1016/j.ygyno.2021.10.088$$gp. S0090825821015523$$n1$$p195-201$$tGynecologic oncology$$v164$$x0090-8258$$y2022
000177465 909CO $$ooai:inrepo02.dkfz.de:177465$$pVDB
000177465 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177465 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000177465 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177465 9141_ $$y2021
000177465 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000177465 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000177465 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000177465 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-16$$wger
000177465 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGYNECOL ONCOL : 2021$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-16
000177465 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bGYNECOL ONCOL : 2021$$d2022-11-16
000177465 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000177465 980__ $$ajournal
000177465 980__ $$aVDB
000177465 980__ $$aI:(DE-He78)C020-20160331
000177465 980__ $$aUNRESTRICTED